183365-29-9

Basic information

• Product Name: Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]-
• CAS NO: 183365-29-9
• Molecular Formula: C13H15N3OS
• Molecular Weight: 261.348
• Mol File: 183365-29-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]-(183365-29-9)
• EPA Substance Registry System: Acetamide, N-[4-[2-(4-aminophenyl)ethyl]-2-thiazolyl]-(183365-29-9)

Safety Data

• Hazardous Substances Data: 183365-29-9(Hazardous Substances Data)

Upstream product

• 16444-13-6 N-(4-formyl-1,3-thiazol-2-yl)acetamide 
• 2767-70-6 (p-nitrobenzyl)triphenylphosphonium bromide 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 51307-38-1 N-[4-(hydroxymethyl)-1,3-thiazol-2-yl]acetamide 
• 111608-67-4 [2-(acetylamino)-1,3-thiazol-4-yl]methyl acetate 
• 737822-88-7 N-{4-[(Z)-2-(4-nitrophenyl)ethenyl]-1,3-thiazol-2-yl}acetamide 

Downstream Products

• 737824-85-0 N-{4-[2-(4-[(iminomethyl)amino]phenyl)ethyl]-1,3-thiazol-2-yl}acetamide 
• 737823-55-1 N-{4-[2-(4-{[(ethylamino)(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide 
• 1426055-69-7 C₁₇H₂₃N₅OS 
• 1426055-70-0 C₁₆H₂₁N₅OS 
• 737823-04-0 N-(4-{2-[4-(ethanimidoylamino)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide 
• 183365-33-5 N-(4-(2-(4-(4,5-dihydro-1,3-thiazol-2-ylamino)phenyl)ethyl)-1,3-thiazol-2-yl)acetamide 
• 737822-92-3 N-{4-[2-(4-{[(benzoylamino)carbonothioyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide 
• 737822-86-5 N-{4-[2-(4-{[amino(imino)methyl]-amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide 

Relevant articles and documents

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.

THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY

A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR1CO- wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: or wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, -NH- or ; D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO2-; and G is lower alkyl, optionally protected amino, -OH, phenyl, or ; and R3 is lower alkyl, provided that when Z is a group of the formula: , then G should not be amino, when Z is a group of the formula: , then G should not be , when Z is a group of the formula: and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.